Medicines Company to seek oritavancin approval at long last
This article was originally published in Scrip
Executive Summary
The Medicines Company will file for US FDA approval in the fourth quarter of 2013 and for European Medicines Agency (EMA) approval in 2014 for its antibiotic oritavancin following a second set of positive Phase III results that showed non-inferiority to vancomycin.